Neos Therapeutics, LP
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$4.8M
Doctors Paid
19,022
Transactions
99,245
2024 Total
$163,636
Payment Breakdown by Category
Food & Beverage$1.8M (37.1%)
Research$788,449 (16.5%)
Travel$292,768 (6.1%)
Consulting$62,975 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.9M | 974 | 38.9% |
| Food and Beverage | $1.8M | 96,704 | 37.1% |
| Unspecified | $788,449 | 472 | 16.5% |
| Travel and Lodging | $292,768 | 1,015 | 6.1% |
| Consulting Fee | $62,975 | 80 | 1.3% |
Payments by Type
General
$4.0M
98,773 transactions
Research
$788,449
472 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A single-dose, single-center, open-label, randomized, 5-arm, parallel study to assess the systematic exposure and safety of four modified-release orally disintegrating tablet formulations of NT0502 (N-desethyloxybutynin) and oxybutynin in healthy adults under fasted conditions - 4008579 (NT0502-1001) | $299,248 | 0 | 4 |
| An Open-Label, Single-Dose Pharmacokinetic Study of ADZENYS XR ODT in Male and Female Children 4 to Less Than 6 Years of Age With Attention-Deficit/Hyperactivity Disorder (ADHD) | $202,439 | 12 | 355 |
| A single-dose, two-period, two-treatment, two-way crossover bioequivalence study of two formulations of methylphenidate extended-release orally disintegrating tablets (XR-ODT), 51.8 mg (2 X 25.9 mg) in healthy adults under fasted conditions. | $152,550 | 0 | 3 |
| An Open-Label, Single-Dose Pharmacokinetic Study of Cotempla XR ODT in Children 4 to Less Than 6 Years of Age With Attention-Deficit/Hyperactivity Disorder (ADHD) | $104,603 | 0 | 107 |
| An Open-Label, Single-Dose Pharmacokinetic Study of ADZENYS XR ODT- in Male and Female Children 4 to Less Than 6 Years of Age With Attention-Deficit-Hyperactivity Disorder -ADHD- | $29,518 | 0 | 2 |
| A Single-Dose, Three-Period, Three-Treatment, Three-Way Crossover Bioavailability Study of a Commercial Scale Formulation of NT0102 Methylphenidate Extended-Release Orally Disintegrating Tablets -XR-ODT- 60 mg -2 x 30 mg- under Fed and Fasted Conditions | $91.64 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Dr. Sanjay Parikh, M.d, M.D | Specialist | Sheffield Village, OH | $27,013 | $0 |
| Dr. Ulla Laakso, Md, MD | Psychiatry | New York, NY | $24,854 | $0 |
| Dr. Stephen Kowalski, M.d, M.D | Specialist | Birmingham, AL | $24,736 | $0 |
| Mark Wright, M.d, M.D | Psychiatry | Lexington, KY | $24,405 | $0 |
| Dr. Lee Cohen, M.d, M.D | Child & Adolescent Psychiatry | Hastings On Hudson, NY | $23,140 | $0 |
| Dr. John Gelinas, M.d, M.D | Specialist | Danbury, CT | $23,055 | $0 |
| Mark Sands, M.d, M.D | Child & Adolescent Psychiatry | Metairie, LA | $22,960 | $0 |
| Ryan Cantville, D.o, D.O | Pediatrics | Jacksonville, FL | $19,579 | $0 |
| Dr. Joel Young, Md, MD | Psychiatry | Rochester Hills, MI | $19,035 | $0 |
| Dr. Ajay Sharma, M.d, M.D | Child & Adolescent Psychiatry | Zanesville, OH | $18,612 | $0 |
| Dr. Mark Matta, Do, DO | Psychiatry | New Castle, PA | $18,559 | $0 |
| Dr. Morris Levinsohn, M.d, M.D | Neurology | Willoughby, OH | $18,333 | $0 |
| Sheila Woods, M.d, M.D | Pediatrics | Mauldin, SC | $18,084 | $0 |
| Mr. Joseph Gagnon, Crnp, CRNP | Psychiatric/Mental Health | Chesterbrook, PA | $16,708 | $0 |
| Ayesha Rashid, M.d, M.D | Psychiatry | Houston, TX | $16,540 | $0 |
| Arman Taghizadeh, M.d, M.D | Psychiatry | Baltimore, MD | $16,323 | $0 |
| Dr. Daniel Tan, M.d, M.D | Psychiatry | Houston, TX | $15,691 | $0 |
| Dr. Richard Jackson, M.d, M.D | Psychiatry | Bloomfield Hills, MI | $15,494 | $0 |
| Unknown Provider | — | — | $15,450 | $0 |
| Hilda Daniel, Md, MD | Psychiatry | Wayne, PA | $14,758 | $0 |
| Christopher Okiishi, Md, MD | Psychiatry | North Liberty, IA | $14,262 | $0 |
| Dr. Randall Kavalier, Do, DO | Psychiatry | West Des Moines, IA | $14,201 | $0 |
| Mr. Ihab Soliman, M.d, M.D | Child & Adolescent Psychiatry | Corona Del Mar, CA | $14,115 | $0 |
| Dr. Jeffrey Alvaro, M.d, M.D | Child & Adolescent Psychiatry | St Petersburg, FL | $13,188 | $0 |
| Dr. Paul Glaser, Md, MD | Psychiatry | Saint Louis, MO | $12,343 | $0 |
Ad
Top Products
- Adzenys XR-ODT $3.9M
- Cotempla XR-ODT $446,701
Associated Products (3)
- Adzenys XR-ODT $3.9M
- Cotempla XR-ODT $447,045
- COTEMPLA XR-ODT $39,690
Payment Categories
- Food & Beverage $1.8M
- Consulting $62,975
- Travel & Lodging $292,768
- Research $788,449
About Neos Therapeutics, LP
Neos Therapeutics, LP has made $4.8M in payments to 19,022 healthcare providers, recorded across 99,245 transactions in the CMS Open Payments database. In 2024, the company paid $163,636. The top product by payment volume is Adzenys XR-ODT ($3.9M).
Payments were distributed across 187 medical specialties. The top specialty by payment amount is Psychiatry ($1.5M to 2,996 doctors).
Payment categories include: Food & Beverage ($1.8M), Consulting ($62,975), Research ($788,449), Travel & Lodging ($292,768).
Neos Therapeutics, LP is associated with 3 products in the CMS Open Payments database.